TrialLancet (London, England)2022

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.

ITAC (INSIGHT 013) Study GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.